Figure 7

EI-tPA, α2M, and S-PrP prevent the decrease in cellular LRP1 α-chain caused by LPS. BMDMs were treated with LPS (0.1 µg/ml) alone and together with EI-tPA (10 nM), α2M (10 nM), or S-PrP (40 nM) for 6 h. Control cells were treated with vehicle. Cell extracts were subjected to immunoblot analysis to detect LRP1 α-chain, LRP1 β-chain, NMDA-R GluN1, and β-actin.